Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial-Reference-Cited by-同舟云学术

Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial

Published:2016-04 Issue: Volume:174 Page:103-110
ISSN:0002-8703
Container-title:American Heart Journal
language:en
Short-container-title:American Heart Journal

Author:

Holman Rury R.,Bethel Mary Angelyn,George Jyothis,Sourij Harald,Doran Zoë,Keenan Joanne,Khurmi Nardev S.,Mentz Robert J.,Oulhaj Abderrahim,Buse John B.,Chan Juliana C.,Iqbal Nayyar,Kundu Sudeep,Maggioni Aldo P.,Marso Steven P.,Öhman Peter,Pencina Michael J.,Poulter Neil,Porter Lisa E.,Ramachandran Ambady,Zinman Bernard,Hernandez Adrian F.

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference37 articles.

1. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants;Danaei;Lancet,2011

2. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial;Stamler;Diabetes Care,1993

3. Diabetes mellitus, fasting glucose, and risk of cause-specific death;Seshasai;N Engl J Med,2011

4. Risk factors for coronary artery disease in non–insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23);Turner;BMJ,1998

5. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies;Sarwar;Lancet,2010

Cited by 81 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Estimated glomerular filtration rate slope and risk of primary and secondary major adverse cardiovascular events and heart failure hospitalization in people with type 2 diabetes: An analysis of the EXSCEL trial;Diabetes, Obesity and Metabolism;2024-07-31

2. Estimating Risk Factor Time Paths Among People with Type 2 Diabetes and QALY Gains from Risk Factor Management;PharmacoEconomics;2024-06-26

3. Regional variation in cause of death in patients with type 2 diabetes: Insights from EXSCEL;American Heart Journal;2024-05

4. Most UK cardiovascular disease trial protocols feature criteria that exclude ethnic minority participants: a systematic review;Journal of Clinical Epidemiology;2024-03

5. The Role of Real-World Evidence in Treatment Decision-Making, Regulatory Assessment, and Understanding the Perspectives of People with Type 2 Diabetes: Examples with Gliclazide MR;Diabetes Therapy;2023-08-21